These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6210423)

  • 1. Cardiovascular dopamine receptors: recent advances in agonists and antagonists of the DA1-receptor.
    Berkowitz BA; Ohlstein EH
    J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S559-63. PubMed ID: 6210423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
    J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526.
    Ohlstein EH; Zabko-Potapovich B; Berkowitz BA
    J Pharmacol Exp Ther; 1984 May; 229(2):433-9. PubMed ID: 6143817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.
    Kerns WD; Arena E; Morgan DG
    Am J Pathol; 1989 Aug; 135(2):339-49. PubMed ID: 2571297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine and dopamine receptors as target sites for cardiovascular drug action.
    Berkowitz BA
    Fed Proc; 1983 Oct; 42(13):3019-21. PubMed ID: 6137421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dopamine receptor activation on the level of cyclic AMP in the trabecular meshwork.
    Karnezis TA; Tripathi BJ; Dawson G; Murphy MB; Tripathi RC
    Invest Ophthalmol Vis Sci; 1989 Jun; 30(6):1090-4. PubMed ID: 2567286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SK&F 82526 and SK&F 83742 on the renal vascular dopamine receptor.
    Schmidt M; Imbs JL; Giesen-Crouse EM; Schwartz J
    J Pharmacol; 1985; 16(1):15-22. PubMed ID: 2582206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.
    Kerns WD; Arena E; Macia RA; Bugelski PJ; Matthews WD; Morgan DG
    Toxicol Pathol; 1989; 17(1 Pt 2):203-13. PubMed ID: 2568682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.
    Hahn RA; Wardell JR; Sarau HM; Ridley PT
    J Pharmacol Exp Ther; 1982 Nov; 223(2):305-13. PubMed ID: 6127401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
    Hieble JP; Owen DA; Harvey CA; Blumberg AL; Valocik RE; DeMarinis RM
    Clin Exp Hypertens A; 1987; 9(5-6):889-912. PubMed ID: 2887313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries.
    Hughes AD; Sever PS
    Blood Vessels; 1989; 26(2):119-27. PubMed ID: 2474340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dopamine (DA) and SKF 82526, a selective DA1-receptor agonist, on vascular resistances in the canine forelimb.
    Grega GJ; Barrett RJ; Adamski SW; Lokhandwala MF
    J Pharmacol Exp Ther; 1984 Jun; 229(3):756-62. PubMed ID: 6144791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man.
    Bakris GL; Weber RR; Nelson K; Elliott WJ; Kaplan E; Murphy MB
    Miner Electrolyte Metab; 1988; 14(6):343-6. PubMed ID: 2906737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist.
    Ohlstein EH; Zabko-Potapovich B; Berkowitz BA
    Eur J Pharmacol; 1985 Dec; 118(3):321-9. PubMed ID: 2867915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of endogenous cyclic AMP levels in ciliary body by SK&F 82526, a novel dopamine receptor agonist.
    De Vries GW; Mobasser A; Wheeler LA
    Curr Eye Res; 1986 Jun; 5(6):449-55. PubMed ID: 2873965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of fenoldopam, SK & F R-87516 and dopamine on renal arterioles in vitro.
    Edwards RM
    Eur J Pharmacol; 1986 Jul; 126(1-2):167-70. PubMed ID: 2875883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dopamine on the cyclic adenosine monophosphate generating system in the rabbit internal carotid and middle cerebral artery.
    Amenta D; Cavallotti C; Collier WL; De Rossi M; Ricci A; Amenta F
    Arch Int Pharmacodyn Ther; 1988; 291():96-103. PubMed ID: 2835025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bulbocapnine is not a selective DA1 receptor antagonist.
    Kohli JD; Glock D; Goldberg LI
    J Pharm Pharmacol; 1986 May; 38(5):401-2. PubMed ID: 2872323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of dopamine1- and dopamine2-receptor agonists on the cAMP generating system in canine coronary and renal arteries.
    Wang WZ; Zhao RR; Qin FZ
    Methods Find Exp Clin Pharmacol; 1994 Dec; 16(10):691-6. PubMed ID: 7723468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.